Effective 1/30/2026: Texas Medicaid Preferred Drug List Updates

Date: 02/05/26

The Texas Health and Human Services Commission (HHSC) published the semi-annual update of the Texas Medicaid Preferred Drug List (PDL) on Friday, January 30, 2026. The update is based on changes presented at the TX Drug Utilization Review (DUR) Board meetings in July and October 2025. Superior HealthPlan follows the Texas Medicaid Vendor Drug Formulary and the PDL.

Additionally, the Texas Drug Utilization Review (DUR) Board reviewed the Hepatitis C drug class for PDL status at its October 24, 2025, meeting. HHSC implemented the Hepatitis C Agents PDL class recommendation on January 1, 2026. This can be viewed on the HHSC PDL Effective January 1, 2026 (PDF).

The table below summarizes some of the anticipated noteworthy changes from the most recent DUR meetings.

Drug Class	Drug Name	Current	Status Change On 1/30/2026
Hepatitis C Agents *As Of January 1, 2026	Qfitlia Pen	Not Reviewed	Preferred*
	Qfitlia Vial	Not Reviewed	Preferred*
Antibiotics, Gastrointestinal	Metronidazole Tablet 125mg	Not Rated	Non-Preferred
	Dificid Tablet	Non-Preferred	Preferred
Colony Stimulating Factors	Neupogen Syringe	Preferred	Non-Preferred
	Fulphila Syringe	Non-Preferred	Preferred
	Granix Vial	Preferred	Non-Preferred
Hepatitis C Agents	Epclusa Tablet	Non-Preferred	Preferred
	Sofosbuvir-Velpatasvir Tablet (Ag)	Non-Preferred	Preferred
Hiv-Aids	Edurant Pediatric Tablet for Suspension	Not Reviewed	Preferred
	Yeztugo Tablet	Not Reviewed	Preferred
	Emtricitabine-Rilpivirne-Tenof Tablet	Not Reviewed	Preferred
Tetracyclines	Doxycycline Hyclate Tablet	Non-Preferred	Preferred
	Doxycycline Monohydrate Tablet	Non-Preferred	Preferred
Opioid Dependance Treatment	Nalmefene Vial	Not Reviewed	Preferred

Please note: The tables are not the complete list of changes. Please reference the Texas Medicaid PDL for a complete list of recommended medications or visit DUR Board webpage on the Texas Vendor Drug website for all decisions.